Ajanta Pharma USA Inc recalls Ranolazine Extended-Release Tablets
- Published
- 7 Oct 2026
- Agency
- FDA
- Country
- United States
The hazard
Failed Dissolution Specifications: below specification
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02
- Brand / company
- Ajanta Pharma USA Inc
- Codes / lots
- Lot: DJ25134, Exp 11/30/2028
- Distribution
- Nationwide in the US.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 7 Oct 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.